Liquid Biopsy in Solid Malignancy

Scarlotta M., Simsek C., Kim A. K.

GENETIC TESTING AND MOLECULAR BIOMARKERS, vol.23, no.4, pp.284-296, 2019 (SCI-Expanded) identifier identifier identifier


The clinical utility of tissue biopsies in cancer management will continue to expand, especially with the evolving role of targeted therapies. "Liquid biopsy" refers to testing a patient's biofluid samples such as blood or urine to detect tumor-derived molecules and cells that can be used diagnostically and prognostically in the assessment of cancer. Many proof-of-concept and pilot studies have shown the clinical potential of liquid biopsies as diagnostic and prognostic markers which would provide a surrogate for the conventional "solid biopsy". In this review, we focus on three methods of liquid biopsy-circulating tumor cells, extracellular vesicles, and circulating tumor DNA-to provide a landscape view of their clinical applicability in cancer management and research.